DE69331526D1 - Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel - Google Patents
Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskelInfo
- Publication number
- DE69331526D1 DE69331526D1 DE69331526T DE69331526T DE69331526D1 DE 69331526 D1 DE69331526 D1 DE 69331526D1 DE 69331526 T DE69331526 T DE 69331526T DE 69331526 T DE69331526 T DE 69331526T DE 69331526 D1 DE69331526 D1 DE 69331526D1
- Authority
- DE
- Germany
- Prior art keywords
- adenovirus
- heart
- guided
- vascular muscle
- smooth vascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
- C07K14/4708—Duchenne dystrophy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97749692A | 1992-11-18 | 1992-11-18 | |
PCT/US1993/011133 WO1994011506A1 (en) | 1992-11-18 | 1993-11-16 | Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69331526D1 true DE69331526D1 (de) | 2002-03-14 |
DE69331526T2 DE69331526T2 (de) | 2002-10-24 |
Family
ID=25525197
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69333886T Expired - Fee Related DE69333886T2 (de) | 1992-11-18 | 1993-11-16 | Adenovirus-gelenkter Gen-Transfer zum Herz-und glattem vaskulären Muskel |
DE69331526T Expired - Fee Related DE69331526T2 (de) | 1992-11-18 | 1993-11-16 | Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69333886T Expired - Fee Related DE69333886T2 (de) | 1992-11-18 | 1993-11-16 | Adenovirus-gelenkter Gen-Transfer zum Herz-und glattem vaskulären Muskel |
Country Status (8)
Country | Link |
---|---|
US (2) | US6297220B1 (de) |
EP (3) | EP0668913B1 (de) |
JP (4) | JPH08506008A (de) |
AT (2) | ATE307212T1 (de) |
AU (1) | AU694097B2 (de) |
CA (1) | CA2149771A1 (de) |
DE (2) | DE69333886T2 (de) |
WO (1) | WO1994011506A1 (de) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
AU727970B2 (en) * | 1993-05-28 | 2001-01-04 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
AU7404994A (en) * | 1993-07-30 | 1995-02-28 | Regents Of The University Of California, The | Endocardial infusion catheter |
US6682728B1 (en) * | 1993-10-13 | 2004-01-27 | The United States Of America As Represented By The Department Of Health And Human Services | Efficient and selective adenoviral-mediated gene transfer into vascular neointima |
US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
US6040157A (en) | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US7186688B1 (en) | 1994-03-08 | 2007-03-06 | Human Genome Sciences, Inc. | Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2 |
CA2184584C (en) | 1994-03-08 | 2003-04-08 | Jing-Shan Hu | Vascular endothelial growth factor 2 |
US7109308B1 (en) | 1994-03-08 | 2006-09-19 | Human Genome Sciences, Inc. | Antibodies to human vascular endothelial growth factor 2 |
US7153827B1 (en) | 1994-03-08 | 2006-12-26 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 and methods of use |
US5932540A (en) | 1994-03-08 | 1999-08-03 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
FR2718150B1 (fr) | 1994-03-29 | 1996-04-26 | Rhone Poulenc Rorer Sa | Virus recombinants, préparation et utilisation en thérapie génique. |
US5851806A (en) * | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
CA2192442C (en) | 1994-06-10 | 2007-09-25 | Imre Kovesdi | Complementary adenoviral vector systems and cell lines |
FR2722507B1 (fr) * | 1994-07-12 | 1996-08-14 | Rhone Poulenc Rorer Sa | Adenovirus comportant un gene codant pour une no synthase |
FR2723697B1 (fr) * | 1994-08-17 | 1996-09-20 | Rhone Poulenc Rorer Sa | Methode de traitement de la restenose par la therapie genique |
US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
AU4502096A (en) * | 1994-11-11 | 1996-06-06 | Arch Development Corporation | A process of inhibiting non-neoplastic pathological cell proliferation |
US5770442A (en) * | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US20030148968A1 (en) * | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
EP0760682A4 (de) * | 1995-02-28 | 1998-09-09 | Univ California | Gentransfer-vermittelte therapie zur gefässneubildung |
US6752987B1 (en) | 1995-02-28 | 2004-06-22 | The Regents Of The University Of California | Adenovirus encoding human adenylylcyclase (AC) VI |
US5792453A (en) * | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
US6306830B1 (en) | 1996-09-05 | 2001-10-23 | The Regents Of The University Of California | Gene therapy for congestive heart failure |
FR2732357B1 (fr) * | 1995-03-31 | 1997-04-30 | Rhone Poulenc Rorer Sa | Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose |
US6783980B2 (en) | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
CA2222140C (en) | 1995-06-15 | 2010-11-23 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US5795872A (en) * | 1995-09-19 | 1998-08-18 | Pharmadigm, Inc. | DNA construct for immunization |
US6090618A (en) | 1996-10-07 | 2000-07-18 | Arch Development Corporation | DNA constructs and viral vectors comprising a smooth muscle promoter |
US7169764B1 (en) | 1995-10-05 | 2007-01-30 | Arch Development Corporation | Promoter for smooth muscle cell expression |
US6121246A (en) * | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
JP2000500017A (ja) * | 1995-11-17 | 2000-01-11 | ウォルフガンク−エム フランツ | 遺伝子治療核酸構造体、その製造と心臓疾患治療へのその利用 |
US20010009904A1 (en) * | 1997-12-30 | 2001-07-26 | Jon A. Wolff | Process of delivering a polynucleotide to a cell via the vascular system |
JP3930052B2 (ja) | 1996-02-15 | 2007-06-13 | バイオセンス・インコーポレイテッド | カテーテルに基づく手術 |
AU2437397A (en) | 1996-07-17 | 1998-02-09 | Medtronic, Inc. | System for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment |
AU2458597A (en) | 1996-07-17 | 1998-02-09 | Medtronic, Inc. | System for genetically treating cardiac conduction disturbances |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
AU7250298A (en) * | 1997-04-25 | 1998-11-24 | Collateral Therapeutics, Inc. | Truncated vegf-related proteins |
US6696423B1 (en) | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
EP2278006A3 (de) | 1997-11-06 | 2011-03-02 | Novartis Vaccines and Diagnostics S.r.l. | Antigene aus Neisseria |
US6151525A (en) * | 1997-11-07 | 2000-11-21 | Medtronic, Inc. | Method and system for myocardial identifier repair |
US7031775B2 (en) | 1997-11-07 | 2006-04-18 | Medtronic, Inc. | Method and system for myocardial infarction repair |
US6775574B1 (en) | 1997-11-07 | 2004-08-10 | Medtronic, Inc. | Method and system for myocardial infarction repair |
CA2317815A1 (en) | 1998-01-14 | 1999-07-22 | Chiron S.P.A. | Neisseria meningitidis antigens |
DE69838526T2 (de) | 1998-02-05 | 2008-07-03 | Biosense Webster, Inc., Diamond Bar | Gerät zum Freisetzen eines Medikaments im Herzen |
CN1295617A (zh) | 1998-02-06 | 2001-05-16 | 科莱特诺医疗公司 | 血管生成因子-血管内皮细胞生长因子vegf的突变体 |
EP1645631B1 (de) | 1998-05-01 | 2007-10-24 | Novartis Vaccines and Diagnostics, Inc. | Neisseria Meningitidis Antigene und Zusammenstellungen |
US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
AU5819599A (en) * | 1998-09-11 | 2000-04-03 | Regents Of The University Of California, The | Recombinant adenovirus for tissue specific expression in heart |
US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
US7223724B1 (en) | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
ES2477194T3 (es) | 1999-04-30 | 2014-07-16 | Novartis Vaccines And Diagnostics S.R.L. | Ant�genos neisseriales conservados |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
DK2275552T3 (en) | 1999-10-29 | 2015-12-07 | Glaxosmithkline Biolog Sa | Neisserial antigenic peptides |
CA2395839A1 (en) | 1999-12-27 | 2001-07-05 | The Regents Of The University Of California | Gene therapy for congestive heart failure |
DK2289545T3 (en) | 2000-01-17 | 2016-09-05 | Glaxosmithkline Biologicals Sa | Supplemented OMV vaccine against meningococcus |
WO2002002148A2 (en) * | 2000-06-30 | 2002-01-10 | Collateral Therapeutics, Inc. | Dual recombinant gene therapy compositions and methods of use |
FR2811678B1 (fr) * | 2000-07-12 | 2002-09-27 | Inst Nat Sante Rech Med | Promoteur specifique du myocarde |
WO2002011769A1 (en) | 2000-08-04 | 2002-02-14 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
DE60138403D1 (de) | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten |
JPWO2002031138A1 (ja) * | 2000-10-06 | 2004-02-19 | 株式会社ディナベック研究所 | 骨格筋に外来遺伝子を導入するためのパラミクソウイルスベクター |
CA2881568C (en) | 2000-10-27 | 2019-09-24 | Novartis Vaccines And Diagnostics, Inc. | Nucleic acids and proteins from streptococcus groups a & b |
EP1361896A2 (de) * | 2001-01-23 | 2003-11-19 | Boston Scientific Corporation | Methode zur lokalen myocardialen injektion zur behandlung ischämischen myocardiums |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
KR20030093316A (ko) | 2001-04-13 | 2003-12-06 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 혈관 내피 성장 인자 2 |
EP1451306A1 (de) * | 2001-11-06 | 2004-09-01 | Medtronic, Inc. | Verfahren und system zur operativen versorgung nach myokardinfarkt |
CN100515494C (zh) | 2001-12-12 | 2009-07-22 | 启龙有限公司 | 抗沙眼衣原体的免疫 |
US20030158112A1 (en) | 2002-02-15 | 2003-08-21 | Johns Hopkins University School Of Medicine | Selective induction of apoptosis to treat ocular disease |
DE60329835D1 (de) | 2002-04-25 | 2009-12-10 | Crucell Holland Bv | Mittel und verfahren zur herstellung von adenovirusvektoren |
US20040044329A1 (en) * | 2002-08-29 | 2004-03-04 | Trudell Leonard A. | Catheter for cardiac injection and method for delivery of therapeutic agents to specified tissues |
WO2004073484A2 (en) * | 2003-02-24 | 2004-09-02 | Yossi Gross | Fully-implantable cardiac recovery system |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
US7818040B2 (en) * | 2003-09-05 | 2010-10-19 | Medtronic, Inc. | Deflectable medical therapy delivery device having common lumen profile |
CN1621094A (zh) * | 2003-11-26 | 2005-06-01 | 犹太大学阿尔伯特爱因斯坦医学院 | 用于调节平滑肌张力的基因转移 |
US7840263B2 (en) | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
ES2407465T3 (es) | 2004-03-29 | 2013-06-12 | Galpharma Co., Ltd. | Nueva proteína galectina 9 modificada y uso de la misma |
US7764995B2 (en) | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
US7828711B2 (en) * | 2004-08-16 | 2010-11-09 | Cardiac Pacemakers, Inc. | Method and apparatus for modulating cellular growth and regeneration using ventricular assist device |
ITRM20040569A1 (it) * | 2004-11-18 | 2005-02-18 | Biogem S C A R L Biotecnologie | Modello animale per lo studio di sostanze ad attivita' cardioterapeutica ed anti-ipertensiva. |
US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
US8060219B2 (en) | 2004-12-20 | 2011-11-15 | Cardiac Pacemakers, Inc. | Epicardial patch including isolated extracellular matrix with pacing electrodes |
US20070265221A1 (en) * | 2006-05-09 | 2007-11-15 | Weiss Robert G | Methods to improve creatine kinase metabolism and contractile function in cardiac muscle for the treatment of heart failure |
WO2008020335A2 (en) | 2006-06-09 | 2008-02-21 | Novartis Ag | Immunogenic compositions for streptococcus agalactiae |
WO2008103336A1 (en) * | 2007-02-21 | 2008-08-28 | Cook Incorporated | Methods for intravascular engraftment in heart |
CA2715765A1 (en) | 2008-02-19 | 2009-08-27 | Celladon Corporation | Compositions for enhanced uptake of viral vectors in the myocardium |
EP3512567B1 (de) * | 2016-09-16 | 2023-11-01 | Icahn School of Medicine at Mount Sinai | Zellspezifische expression von modrna |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA858044B (en) * | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
EP0456640A1 (de) | 1988-12-13 | 1991-11-21 | UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Genetisch erzeugte endothelzellen und deren verwendung |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US5698531A (en) | 1989-03-31 | 1997-12-16 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
SE464777B (sv) | 1989-10-03 | 1991-06-10 | Be Ge Ind Ab | Progressiv luftfjaeder |
IE911115A1 (en) | 1990-04-10 | 1991-10-23 | Canji Inc | Gene therapy for cell proliferative diseases |
FR2681786A1 (fr) * | 1991-09-27 | 1993-04-02 | Centre Nat Rech Scient | Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires. |
-
1993
- 1993-11-16 AT AT99109240T patent/ATE307212T1/de not_active IP Right Cessation
- 1993-11-16 JP JP6512466A patent/JPH08506008A/ja active Pending
- 1993-11-16 EP EP94901544A patent/EP0668913B1/de not_active Revoked
- 1993-11-16 CA CA002149771A patent/CA2149771A1/en not_active Abandoned
- 1993-11-16 WO PCT/US1993/011133 patent/WO1994011506A1/en not_active Application Discontinuation
- 1993-11-16 DE DE69333886T patent/DE69333886T2/de not_active Expired - Fee Related
- 1993-11-16 AU AU56093/94A patent/AU694097B2/en not_active Ceased
- 1993-11-16 EP EP02022269A patent/EP1321526A3/de not_active Withdrawn
- 1993-11-16 DE DE69331526T patent/DE69331526T2/de not_active Expired - Fee Related
- 1993-11-16 EP EP99109240A patent/EP0957172B1/de not_active Expired - Lifetime
- 1993-11-16 AT AT94901544T patent/ATE212665T1/de not_active IP Right Cessation
-
1997
- 1997-11-18 US US08/972,831 patent/US6297220B1/en not_active Expired - Fee Related
-
1998
- 1998-11-05 US US09/186,968 patent/US6436907B1/en not_active Expired - Fee Related
-
2002
- 2002-09-19 JP JP2002274149A patent/JP2003102474A/ja not_active Withdrawn
-
2004
- 2004-06-04 JP JP2004167855A patent/JP2004313198A/ja active Pending
-
2006
- 2006-03-15 JP JP2006071837A patent/JP2006212034A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US6297220B1 (en) | 2001-10-02 |
EP0957172A3 (de) | 2000-03-15 |
ATE212665T1 (de) | 2002-02-15 |
AU694097B2 (en) | 1998-07-16 |
EP1321526A2 (de) | 2003-06-25 |
JPH08506008A (ja) | 1996-07-02 |
DE69333886D1 (de) | 2006-03-02 |
DE69333886T2 (de) | 2006-07-27 |
ATE307212T1 (de) | 2005-11-15 |
JP2006212034A (ja) | 2006-08-17 |
US6436907B1 (en) | 2002-08-20 |
AU5609394A (en) | 1994-06-08 |
EP0668913A1 (de) | 1995-08-30 |
EP0668913B1 (de) | 2002-01-30 |
CA2149771A1 (en) | 1994-05-26 |
JP2003102474A (ja) | 2003-04-08 |
WO1994011506A1 (en) | 1994-05-26 |
EP1321526A3 (de) | 2003-07-02 |
EP0957172B1 (de) | 2005-10-19 |
JP2004313198A (ja) | 2004-11-11 |
EP0957172A2 (de) | 1999-11-17 |
DE69331526T2 (de) | 2002-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69331526T2 (de) | Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel | |
FR2681786B1 (de) | ||
GEP20033145B (en) | Stem Cell Factor | |
ATE236263T1 (de) | Adeno-assozierter virus 2 basalvektoren | |
DE69233010D1 (de) | Universale spenderzellen | |
FI955552A0 (fi) | Adenoviraalisia eläinperäisiä vektoreita ja niiden käyttö geeniterapiassa | |
EP0935001A4 (de) | Neuartige vegf-ähnliche faktoren | |
ATE240401T1 (de) | Expression von exogenen polynukleotidsequenzen in wirbeltieren | |
EP0637966A1 (de) | Warte-effekt bei tumorzerstörender therapie. | |
IL74947A0 (en) | Preparation of polypeptides having human gamma interferon activity | |
EP0321196A3 (de) | Transkriptionsaktivator des 780 T-DNA-Gens | |
MY101718A (en) | Medicated cosmetic compositions | |
Schjerling | The basics of gene doping | |
AU3078684A (en) | Improved e. coli plasmid containing modified 5' cipoprotein sequence | |
IL192893A0 (en) | Cell-based gene therapy for the pulmonary system | |
DK0555785T3 (da) | Glat-muskel-mitogent stof og DNA, der koder herfor | |
Paçarizi et al. | The expression of growth factors in human melanomas | |
Chung | Toxicity of the Adenoviral Vector Mediated Gene Therapy | |
周洁民 et al. | Expression of Human Factor Ⅸ cDNA in Mice by Implants of Genetically Modified Skin Fibroblasts From a Hemophilia B Patient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8339 | Ceased/non-payment of the annual fee |